Categories Earnings, Other Industries

Upbeat Q2 results no help to Gilead Sciences as CEO resignation sends shares down

Lower product sales and prescription trends continued to batter Gilead Sciences (GILD), as earnings slipped more than 40% in the second quarter of FY2018. However, the results beat expectations. The earnings announcement was preceded by the company updating that John F. Milligan will step down as CEO and President. The upbeat results were marred by the resignation, as shares slipped 1.6% in extended trading after market close on Wednesday.

Milligan, who was with Gilead for 28 years, plans to remain in his current position till the year-end as the Board of Directors searches for a successor.

With revenue tumbling 21% to $5.6 billion, the biopharma giant saw a 41% slide in second-quarter earnings to $1.82 billion or $1.39 per share. Non-GAAP EPS plunged 25% to $1.91.

The previous quarter, lower sales of Harvoni and Sovaldi across all major markets and lower sales of Epclusa in the US due to increased competition hurt product sales. This quarter, however, Genvoya sales lifted sales a bit, offset by Truvada.


CEO Milligan stepping down sparks a slide in share price even after upbeat results


Gilead also saw research and development expenses (R&D) skyrocket to $1.2 billion this quarter from $864 million a year ago.

Gilead also tweaked its full-year 2018 guidance, as effective tax rate is now expected to be 19-21%, while the combined impact of acquisition-related, up-front collaboration, stock-based compensation, and other expenses on diluted EPS is touted to be $1.50-1.60 now.

Earlier, the biopharma company said it expects full-year 2018 net product sales of $20 billion to $21 billion and EPS of $1.41-1.51. Gilead continues to expect product gross margin of 85-87%, with R&D expenses in the range of $3.40 billion to $3.60 billion.

Also Read:  Blackstone's buying spree continues with Gramercy deal

With not so impressive results, one can say the CEO stepping down was a long way coming. “Today, Gilead has the right strategy in place to successfully execute on its mission of improving the lives of people with some of the world’s most serious diseases, led by a robust HIV franchise, an industry-leading cell therapy platform and a late-stage pipeline in NASH and inflammation,” said John C. Martin, Chairman of the Board of Directors.

However, CEO John F. Milligan hinted that it was high time for a vacation, who said, “I’m looking forward to a well-deserved break and will then move on to new and different opportunities.” Dr. Milligan will also resign from the Gilead Board by year-end. Chairman John C. Martin also said he would step down from the board when a new CEO joins the company.

Gilead Sciences post upbeat Q2 results, CEO resigns

Most Popular

Levi Strauss (LEVI): Digital maintains momentum amid pandemic-induced store closures

Amid the COVID-19 pandemic, several retailers were forced to close their stores but in turn witnessed a pickup in their digital business. Levi Strauss & Co. (NYSE: LEVI) is the

Mattel’s (MAT) transformation plan will depend on how pandemic plays out

The ongoing market turmoil has upset the growth strategy set by Mattel, Inc. (NASDAQ: MAT), with focus on transitioning into an IP-driven company. Currently, the maker of legendary brands like

Lemonade (LMND): A successful IPO of 2020

The usage of artificial intelligence (AI) has accelerated rapidly in the fintech industry. Many insurance companies are using AI to compete with their competitors. These insurance companies use AI in

2 thoughts on “Upbeat Q2 results no help to Gilead Sciences as CEO resignation sends shares down

Comments are closed.